Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Jan 1;107(1):e303-e314.
doi: 10.1210/clinem/dgab595.

Associations of Endogenous Hormones With HDL Novel Metrics Across the Menopause Transition: The SWAN HDL Study

Affiliations
Observational Study

Associations of Endogenous Hormones With HDL Novel Metrics Across the Menopause Transition: The SWAN HDL Study

Samar R El Khoudary et al. J Clin Endocrinol Metab. .

Abstract

Context: Novel metrics of high-density lipoprotein (HDL) (subclasses, lipid content, and function) may improve characterization of the anti-atherogenic features of HDL. In midlife women, changes in these metrics vary by time relative to the final menstrual period (FMP), supporting a contribution of estradiol (E2) and follicle-stimulating hormone (FSH).

Objective: We tested associations of endogenous E2 and FSH with novel HDL metrics and assessed whether these associations varied by time relative to FMP.

Methods: This study was a longitudinal analysis from the Study of Women's Health Across the Nation (SWAN) HDL study, using a community-based cohort of 463 women, baseline mean age 50.2 (2.7) years. The main outcome measures were HDL cholesterol efflux capacity (HDL-CEC), HDL phospholipids (HDL-PL), HDL triglycerides (HDL-Tg), HDL particles (HDL-P), HDL size, and HDL cholesterol (HDL-C).

Results: In multivariable analyses, E2 was positively associated with HDL size, large HDL-P, HDL-CEC, and HDL-Tg, but negatively with medium HDL-P (P values < 0.05). The positive association between E2 and HDL-Tg was stronger 2 years post-FMP than before, (interaction P = 0.031). FSH was positively related to total and medium HDL-P, but negatively to HDL size, large HDL-P, and HDL-CEC per particle (P values < 0.05). Associations of higher FSH with greater total HDL-P and smaller HDL size were only evident at/after menopause (interaction P values < 0.05).

Conclusion: Some of the associations linking E2 and FSH with novel HDL metrics were vulnerable to time relative to menopause onset. Whether a late initiation of hormone therapy relative to menopause could have a detrimental effect on lipid content of HDL particles should be tested in the future.

Keywords: climacteric; follicle-stimulating hormone; high-density lipoprotein; sex hormones; subclasses.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Adjusted means of HDL-Tg by E2 tertiles stratified by time relative to the FMP. Models adjusted for race/ethnicity, time-varying age, cycle day of blood draw, log-transformed hsCRP, and BMI. *Significantly different from Low E2.
Figure 2.
Figure 2.
Adjusted means of (a) ApoA-I, (b) Total HDL-P, (c) HDL size by FSH tertiles stratified by time relative to the FMP. Models adjusted for race/ethnicity, time-varying age, cycle day of blood draw, log-transformed hsCRP, and BMI. *Significantly different from Low FSH.

Comment in

References

    1. Voight BF, Peloso GM, Orho-Melander M, et al. . Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet. 2012;380(9841):572-580. - PMC - PubMed
    1. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA. 1986;256(20):2835-2838. - PubMed
    1. Sharrett AR, Ballantyne CM, Coady SA, et al. ; Atherosclerosis Risk in Communities Study Group . Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001;104(10):1108-1113. - PubMed
    1. Barter PJ, Caulfield M, Eriksson M, et al. ; ILLUMINATE Investigators . Effects of torcetrapib in patients at high risk for coronary events. n Engl j Med. 2007;357(21):2109-2122. - PubMed
    1. Nissen SE, Tardif JC, Nicholls SJ, et al. ; ILLUSTRATE Investigators . Effect of torcetrapib on the progression of coronary atherosclerosis. n Engl j Med. 2007;356(13):1304-1316. - PubMed

Publication types